SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that the CDND intends to purchase up to 15,325 courses of oral TPOXX (tecovirimat) over four years as specified in the ACAN, with an initial purchase of 2,500 courses. The ACAN is required to remain open for at least 15 days, during which time a potential alternative supplier may submit a competing Statement of Capabilities.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of options under its 2018 Biomedical Advanced Research and Development Authority (BARDA) contract (“19C BARDA Contract”) worth a total of approximately $101.3 million for the procurement of oral TPOXX for the treatment of smallpox (tecovirimat). Deliveries of oral TPOXX to maintain national preparedness under these option exercises are expected to start in the second quarter of 2020 and be completed by April 2021. With the above-mentioned exercise of options, all procurement options under CLIN 9 (contract line item number 9) of the 19C BARDA Contract have been exercised.
- Company Recently Announced Exercise of Contract Options Totaling $101.3 million - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, May 06, 2020 -- SIGA.
For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission including, without limitation, the company's annual report on Form 10-K for the year ended December 31, 2019, and its subsequent reports on Form 10-Q and Form 8-K. I will now turn the conference over to Phil Gomez, chief executive officer of SIGA. Today, I'm joined by Dan Luckshire, our CFO; and Dr. Dennis Hruby, our chief scientific officer. On this call, Dan will be providing an update of our Q1 financial results, recent orders for TPOXX from the Canadian military in BARDA and expectations related to these orders.
Q4 2019 SIGA Technologies Inc Earnings Call
NEW YORK, NY / ACCESSWIRE / March 5, 2020 / SIGA Technologies, Inc. (SIGA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30 PM Eastern ...
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 5, 2020 after release of year end financial results. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. Participants may also access the call, by dialing (877) 407-6184 for domestic callers or (201) 389-0877 for international callers.
Q1 2020 SIGA Technologies Inc Earnings Call
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has reached concurrence with the US Food and Drug Administration (FDA) that no further clinical studies will be required for the IV formulation of TPOXX (tecovirimat), and SIGA anticipates filing the New Drug Application (NDA) for this formulation in 2020. Given that the efficacy of TPOXX was previously established in animal models used to support the development and approval of the oral formulation, the FDA will not require additional efficacy data to support the NDA for the IV formulation.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Asia Conference in Kuala Lumpur, Malaysia. Dr. Gomez will present on “Medical Preparedness for Chemical, Biological, Radiological and Nuclear Defense (CBRNe) Events” at 4:00 p.m. Malaysia Time on Wednesday, October 23, 2019.
- Announces Expectations for Product Delivery to BARDA -- Announces $50 Million Share Repurchase Program -- Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK,.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Wednesday, May 6, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer. Participants may also access the call, by dialing (877) 407-6184 for domestic callers or (201) 389-0877 for international callers.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference at 3:00 p.m. EDT on Thursday, October 3, 2019 in New York. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX® (tecovirimat) in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform. The collaboration will provide Turnstone with access to SIGA’s TPOXX oral antiviral capsules for use if required in future clinical programs. “TPOXX has potential as a new tool to support the adoption of oncolytic vaccinia virus immunotherapies, including those being developed by Turnstone,” said Dr. Phil Gomez, CEO of SIGA.
We can judge whether SIGA Technologies Inc. (NASDAQ:SIGA) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that it intends to award a contract to fund regulatory filing with Health Canada for approval of oral TPOXX®. The ACAN is required to remain open for approximately 15 days, during which time a potential alternative supplier who meets the ACAN requirements for a smallpox anti-viral therapy that has been approved by national regulatory authority may submit a competing Statement of Capabilities.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has awarded a contract to Meridian Medical Technologies, Inc. (“Meridian”, a Pfizer Company) (Canadian Contract), in which it will purchase up to 15,325 courses of oral TPOXX (tecovirimat) over four years for a total value of $14.3 million, with an initial purchase of 2,500 courses for $2.3 million. “The current COVID-19 pandemic has reminded us all that preparedness with medical countermeasures is critical for responding effectively to any infectious disease outbreak,” said Dr. Phil Gomez, CEO of SIGA Technologies.
The big shareholder groups in SIGA Technologies, Inc. (NASDAQ:SIGA) have power over the company. Insiders often own a...